BIOAFFINITY TECHNOLOGIES INC (BIAF)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$15.27+19.48%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · BIAF
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 12.3% |
| Our one-year growth estimate | diamond | 5.3% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 7.0 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 33 industry peers · Company calendar date is not available
BIAF — dividend update
Dated 2026-08-14
Entry into a Material Definitive Agreement. On August 12, 2026, bioAffinity Technologies, Inc. (the “ Company ”) entered into a securities purchase agreements (the “ Purchase Agreement ”) with an institutional investor (“the “ Purchaser ”) for the issuance and sale in a private placement (the “ Private Placement ”) of (i) pre-funded warrants (the “ Pre-Funded Warrants ”) at a purchase price of $0.4657 per Pre-Funded Warrant to purchase up to an aggregate of 8,462,027 shares (the “ Pre-Funded…
Why it matters: New partnerships can help develop products and reach more markets. This supports growth.
Supportive ifAnnouncement of at least one new strategic partnership by Q4 2026.
Worry ifNo new partnerships announced by Q4 2026.
Why it matters: Strong revenue growth shows that CyPath Lung is selling well. This is good for the business.
Supportive ifQ3 revenue growth exceeds 20% year over year.
Worry ifQ3 revenue growth falls below 10% year over year.
Why it matters: How many people join the trial is important. It helps show how well CyPath Lung works.
Supportive ifEnrollment reaches or exceeds 50% of the target number of patients within the next quarter.
Worry ifEnrollment stalls or falls below 30% of the target number of patients.
Why it matters: Smaller losses mean better cost control. It also shows better operations.
Supportive ifQ2 operating losses were less than negative $3.6M.
Worry ifQ2 operating losses were worse than negative $3.6M.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$377 on $10,000 · ±3.8% | How much price usually moves either way. |
| Bad day | $1,486 loss on $10,000 · 14.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,711 loss on $10,000 · 97.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Financial results will show revenue growth and losses. This is important for investor trust.
Watch forRevenue for Q2 2026 shows significant growth compared to Q1 2026.
Also watch forRevenue for Q2 2026 declines compared to Q1 2026.
Why it matters: Updates on this partnership could improve lung cancer screening for veterans and grow market reach.
Supportive ifThere is an announcement about the progress or results of the Philips partnership.
Worry ifNo updates or bad news about the Philips partnership are reported.
Why it matters: If trials go well, it could show that CyPath Lung works. This may help more people use it.
Supportive ifIn the next quarter, patient enrollment in the trial may reach 50% of the goal.
Worry ifEnrollment stalls or falls short of expectations.
Why it matters: This would show that the company is starting to grow revenue after recent declines.
Supportive ifQ2 revenue was over $1.4M. This shows growth is speeding up.
Worry ifQ2 revenue was below $1.4M. This shows a continued drop.
Why it matters: If test volume growth slows, it may mean fewer doctors are using the tests. It could also mean the market is full.
Worry ifCyPath Lung test volume growth remains above 200% year over year.
Less concerning ifTest volume growth falls below 200% year over year.
Why it matters: Results from the trial could validate CyPath Lung as a standard of care, impacting future sales.
Watch forThe clinical trial shows good results for CyPath Lung's effectiveness.
Also watch forThe clinical trial shows poor results for CyPath Lung's effectiveness.
Why it matters: The results will impact the company's status and how investors feel.
Worry ifThe company wins the appeal against the delisting notice. It keeps its Nasdaq listing.
Less concerning ifThe appeal fails, leading to a confirmed delisting from Nasdaq.
Why it matters: Earnings results will provide key insights into revenue trends and financial health.
Watch forThe earnings report shows revenue growth that is better than expected.
Also watch forThe earnings report shows revenue drop or big losses.
Why it matters: More orders from doctors show the test is gaining acceptance and market reach.
Supportive ifThe number of offices ordering CyPath Lung rises by over 155% each year.
Worry ifThe number of offices ordering CyPath Lung rises by less than 155% each year.
Why it matters: This partnership may help reach more people and build trust, especially with veterans.
Supportive ifShare key milestones or results from the partnership. These help veterans get lung cancer screenings.
Worry ifNo updates or progress reported on the partnership within the next quarter.
Why it matters: Better cash flow shows stronger finances. It also shows good management.
Supportive ifCash from operations reported less negative than $3.2M in Q2.
Worry ifCash from operations reported more negative than $3.2M in Q2.
Why it matters: Good results from the offering could help investor trust and funding.
Supportive ifNew projects or plans were announced. They are funded by the public offering.
Worry ifNo updates or negative news regarding the use of funds from the offering.
Why it matters: Good cash flow management is key for keeping operations and funding growth.
Worry ifPositive cash flow in future quarters shows good cost management.
Less concerning ifWatch for ongoing cash issues or worsening cash flow.
Why it matters: Progress in this trial could validate CyPath Lung as a standard of care, boosting credibility.
Supportive ifLook for news on patient enrollment or good results from the trial.
Worry ifWatch for delays in the trial or bad results.